Navigation Links
Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Date:6/1/2008

- Phase 2 Data To Be Presented Along With Updated Phase 1 Colorectal Cancer

Data at ASCO Annual Meeting -

SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced positive preliminary results from its ongoing randomized Phase 2 clinical trial in patients with metastatic colorectal cancer (CRC) and updated results from an ongoing Phase 1 CRC trial. Preliminary data suggest that picoplatin given in combination with 5-fluorouracil and leucovorin (FOLPI) and oxaliplatin given in combination with 5-fluorouracil and leucovorin (FOLFOX) may have similar anti-tumor activity in metastatic CRC.

The Company will present the Phase 1 and 2 picoplatin data (abstract #4100) in the General Poster Session during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of multiple solid tumor indications.

"The comparison of picoplatin and oxaliplatin in combination with 5-fluorouracil and leucovorin has provided encouraging preliminary results," said Robert De Jager, M.D., chief medical officer of Poniard. "These data support our strategy of developing picoplatin as a preferred platinum for the first-line treatment of metastatic CRC. The ongoing Phase 2 trial could support advancement of picoplatin into a registration trial."

Phase 2 CRC Study Preliminary Results

The randomized, controlled, 100-patient P
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015   Vestagen Technical Textiles, Inc. ... , has recently received two notable innovation awards. The ... that recognizes innovations with potential to create a positive ... in New York City , VESTEX ... "Protection & Safety" category. The awards honor excellence in ...
(Date:4/24/2015)... , Apr. 24, 2015 Research and ... announced the addition of the "Lab ... tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station) & End User ... Global Forecast to 2020" report to ... accessories market is expected to reach $504.7 ...
(Date:4/24/2015)... , April 24, 2015 Hi-Tech ... that such was not the product of reliable scientific ... a reliable basis for allegations of adulteration. The ... on a false premise, or misguided hope, that ... these studies are contradicted by multiple other studies ...
Breaking Medicine Technology:VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6
... WIRE)--Jun 7, 2007 - Inovio Biomedical,Corporation (AMEX:INO), ... cancers and infectious diseases and a novel ... today that the,company's partner, Vical Incorporated, presented ... subjects from an ongoing Phase I,clinical trial ...
... clinically meaningful pain relief within 5,minutes of dosing ... 2007 - Archimedes Pharma Ltd,("Archimedes"), a European specialty ... Phase II study of Nasalfent(r),an innovative fentanyl citrate ... convenient treatment for breakthrough cancer,pain. Data were presented ...
Cached Medicine Technology:Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3
(Date:4/24/2015)... Illinois (PRWEB) April 24, 2015 Multi ... includes septic tank pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 ... to start the program. This does not include any ... applicable. Save $25-$65 per person. If someone is part ... or two tanks totaling approximately 2500 gallons or more, ...
(Date:4/24/2015)... The Fastest Fat Loss Week Ever, released ... of the Xtreme Fat Loss Diet, has been causing a ... blueprint that claims to help one lose belly fat in ... Stevenson, prompting an investigative review. , "Our Fastest Fat ... years researching and experimenting with these methods on their clients ...
(Date:4/24/2015)... April 24, 2015 The first step ... the mind. , For meditation and yoga teacher Stine ... have been invaluable tools that allow her to experience ... She has been a teacher since 2006, and through ... inner state of being. , “I love sharing this ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new ... cognition. , A unique combination of herbs and ... Flavonoid Complex apart from other antioxidant supplements. This ... support antioxidation versus the use of single or ... extract, Resveratrol, Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with ...
(Date:4/24/2015)... 24, 2015 Insuranceautoquote.info has released a ... insurance premiums . , Lowering auto insurance prices ... to simply find better offers for their financial budget. ... it does not require any registration. , Comparing ... There are multiple agencies that sell coverage and this ...
Breaking Medicine News(10 mins):Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2
... PALM SPRINGS, Calif., Aug. 6 Desert Oasis Healthcare, an ... highlighted in a USA Today story discussing the country,s most ... Medicare Plan Obama calls ,wasteful," Desert Oasis is described as ... and reduce hospital readmissions." , , (Photo: ...
... 6: Numbers were impressive at June,s CPhI China ... China - which together form Asia ... equipment communities. , , Staged by UBM at Shanghai,s ... 1,651 exhibitors from 17 countries and welcomed nearly 23,700 visits. , ...
... UV exposure associated with skin inflammation in study of ... sun,s ultraviolet (UV) rays may trigger certain types of ... , "This study found that women who lived in ... developed an autoimmune muscle disease called myositis were more ...
... , , SAN DIEGO, Aug. 6 ... focused on the treatment of obesity, today announced unaudited financial results for ... Three Months Ended June 30, 2009 , As of ... and an additional $37.4 million in investment securities, available-for-sale. In July ...
... , EATONTOWN, N.J., Aug. 6 Osteotech, Inc. ... of biologic products for regenerative healing, announced today that its management ... Global Growth Conference at the InterContinental Hotel in Boston on Thursday, ... A live, listen-only webcast of the presentation will be available ...
... , , , ... , Twitter was shut down Thursday morning August 6 due to a denial of service ... at Integralis, can discuss: , , - Why are Web 2.0 ... is more like a human brain than a simple website. Its users are within ...
Cached Medicine News:Health News:Desert Oasis Healthcare Featured in USA Today 2Health News:Desert Oasis Healthcare Featured in USA Today 3Health News:Desert Oasis Healthcare Featured in USA Today 4Health News:China Pharma Events Keep Growing For UBM 2Health News:China Pharma Events Keep Growing For UBM 3Health News:Sunlight May Cause Rash in Autoimmune Disease 2Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 2Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 3Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 4Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 5Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 6Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 7Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 8Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 9Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 10Health News:Integralis Expert Resource Available to Discuss Twitter Denial of Service Attack and Web 2.0 Security 2
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... stone manipulation and removal in the urinary tract. ... retain its shape following extreme torsion. The unique ... allowing the basket to open at the base ... tipless design reduces the likelihood of mucosal damage ...
Medicine Products: